Lymphatic and capillary invasion patterns in triple negative breast cancer

American Surgeon

Volumn 78, Issue 11, 2012, Pages 1238-1242

  Yaman, Sebnem ^a   Gumuskaya, Berrak ^a   Ozkan, Cigdem ^a   Aksoy, Sercan ^a   Guler, Gulnur ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PODOPLANIN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CAPILLARY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; POSTMENOPAUSE; PREMENOPAUSE; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CAPILLARIES; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASM INVASIVENESS;

EID: 84867913382     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:1721-8. (Pubitemid 46668532)
3. Carey LA, Perou CM, Livasy CA, et al. Breast canser subtypes and survival in the Carolina Breast Canser Study. JAMA 2006;295:249-250.
4. Cleator S, Heller W, Coombes RC, et al. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44. (Pubitemid 46291713)
5. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-7. (Pubitemid 46631305)
6. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in population based study. Cancer Epidemiol Markers Prev 2007;16:439-43. (Pubitemid 46548646)
7. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071-82.
8. Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple negativity in nodenegative breast cancer. BMC Cancer 2008;8:307.
9. Lundin J, Lundin M, Holli K, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001;19:28-36.
10. Henderson IC, Patek AJ, et al. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998;52:261-88. (Pubitemid 29056100)
11. Rosen PP, Groshen S, Kinn DW, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090.
12. Shoup M, Malinzak L, Aranha VH, et al. Predictors of axillary lymph node metastases in T1 breast carcinoma. Am Surg 1999;65:748-52.
13. Chua B, Ung O, Taylor R, et al. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 2001;71:723-8. (Pubitemid 34014708)
14. Kato T, Kameoka S, Kimura T, et al. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer 2003;88:1900-8. (Pubitemid 36829665)
15. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-12. (Pubitemid 38963023)
16. Braun M, Flucke U, Debald M, Walgenbach-Bruenagel G. Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases. Breast Cancer Res Treat 2008;112:503-11.
17. O'Rourke S, Galea MH, Morgan M, et al. Local recurrence after simple mastectomy. Br J Surg 1994;81:386-9. (Pubitemid 24124814)
18. Gluz O, Liedtke C, Gottschalk N, et al. Triple negative breast cancer - current status and future directions. Ann Oncol 2009;20:1913-27.
19. Lin NU, Claus E, Sohl J. Sites of distance recurrence and clinical outcomes in patient with metastatic triple negative breast cancer. Cancer 2008;113:2638-45.
20. Dawood S, Broglio K, Esteva FJ. Survival among women with triple negative breast cancer and brain metastases. Ann Oncol 2009;20:621-7.
21. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999;79:243-51. (Pubitemid 29110654)
22. Birner P, Schindl M, Obermair A, et al. Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res 2000;20:2981-5.
23. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913-21. (Pubitemid 40315647)
24. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74. (Pubitemid 32878711)
25. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44. (Pubitemid 352009225)
26. Dent R, Trudea M, Pritchard KI, et al. Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;109:1721-8.
27. Mohammed RA, Martin SG, Gill MS, et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007;31:1825-33. (Pubitemid 350175809)
28. Mohammed RA, Martin SG, Mahmmod AM, et al. Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. J Pathol 2011;223:358-65.
29. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 2006;94:1643-9. (Pubitemid 43924927)
30. Ding GP, Ye CS, Liu MF, et al. Relationship between D2-40-labeled lymphatic vessel invasion and lymph node metastasis of breast cancer [in Chinese]. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30:2301-3.
31. Kuroda H, Nakai M, Ohnisi K, et al. Vascular invasion in triple-negative carcinoma of the breast identified by endothelial lymphatic and blood vessel markers. Int J Surg Pathol 2010;18:324-9.